Establishment of a Gorlin syndrome model from induced neural progenitor cells exhibiting constitutive GLI1 expression and high sensitivity to inhibition by smoothened (SMO).
GLI1
PTCH1
hedgehog signaling pathway
induced pluripotent stem cells
vismodegib
Journal
Laboratory investigation; a journal of technical methods and pathology
ISSN: 1530-0307
Titre abrégé: Lab Invest
Pays: United States
ID NLM: 0376617
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
04
06
2019
accepted:
14
10
2019
revised:
04
10
2019
pubmed:
24
11
2019
medline:
21
10
2020
entrez:
24
11
2019
Statut:
ppublish
Résumé
The hedgehog signaling pathway is a vital factor for embryonic development and stem cell maintenance. Dysregulation of its function results in tumor initiation and progression. The aim of this research was to establish a disease model of hedgehog-related tumorigenesis with Gorlin syndrome-derived induced pluripotent stem cells (GS-iPSCs). Induced neural progenitor cells from GS-iPSCs (GS-NPCs) show constitutive high GLI1 expression and higher sensitivity to smoothened (SMO) inhibition compared with wild-type induced neural progenitor cells (WT-NPCs). The differentiation process from iPSCs to NPCs may have similarity in gene expression to Hedgehog signal-related carcinogenesis. Therefore, GS-NPCs may be useful for screening compounds to find effective drugs to control Hedgehog signaling activity.
Identifiants
pubmed: 31758086
doi: 10.1038/s41374-019-0346-2
pii: S0023-6837(22)01253-3
doi:
Substances chimiques
Anilides
0
GLI1 protein, human
0
HhAntag691
0
PTCH1 protein, human
0
Patched-1 Receptor
0
Pyridines
0
SMO protein, human
0
Smoothened Receptor
0
Zinc Finger Protein GLI1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
657-664Références
Dessaud E, Yang LL, Hill K, Cox B, Ulloa F, Ribeiro A, et al. Interpretation of the sonic hedgehog morphogen gradient by a temporal adaptation mechanism. Nature. 2007;450:717–20.
doi: 10.1038/nature06347
Petrova R, Joyner AL. Roles for Hedgehog signaling in adult organ homeostasis and repair. Development. 2014;141:3445–57.
doi: 10.1242/dev.083691
Coni S, Infante P, Gulino A. Control of stem cells and cancer stem cells by Hedgehog signaling: pharmacologic clues from pathway dissection. Biochem Pharmacol. 2013;85:623–8.
doi: 10.1016/j.bcp.2012.11.001
Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, Gutiérrez García-Rodrigo C, Fargnoli MC. Understanding the molecular genetics of basal cell carcinoma. Int J Mol Sci. 2017;18:2485.
Yang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourboulas M, et al. Medulloblastoma can be initiated by deletion of patched in lineage-restricted progenitors or stem cells. Cancer Cell. 2008;14:135–45.
doi: 10.1016/j.ccr.2008.07.003
Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov. 2006;5:1026–33.
doi: 10.1038/nrd2086
Ruch JM, Kim EJ. Hedgehog signaling pathway and cancer therapeutics: progress to date. Drugs. 2013;73:613–23.
doi: 10.1007/s40265-013-0045-z
Gorojankina T. Hedgehog signaling pathway: a novel model and molecular mechanisms of signal transduction. Cell Mol Life Sci. 2016;73:1317–32.
doi: 10.1007/s00018-015-2127-4
Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, DiGiovanna JJ, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69:299–308.
doi: 10.1002/(SICI)1096-8628(19970331)69:3<299::AID-AJMG16>3.0.CO;2-M
Bresler SC, Padwa BL, Granter SR. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Head Neck Pathol. 2016;10:119–24.
doi: 10.1007/s12105-016-0706-9
Kelleher FC, Fennelly D, Rafferty M. Common critical pathways in embryogenesis and cancer. Acta Oncol. 2006;45:375–88.
doi: 10.1080/02841860600602946
Fontana A, Wrobel B. Embryogenesis, morphogens and cancer stem cells: putting the puzzle together. Med Hypotheses. 2013;81:643–9.
doi: 10.1016/j.mehy.2013.07.021
Quail DF, Siegers GM, Jewer M, Postovit LM. Nodal signalling in embryogenesis and tumourigenesis. Int J Biochem Cell Biol. 2013;45:885–98.
doi: 10.1016/j.biocel.2012.12.021
Cao Y. Tumorigenesis as a process of gradual loss of original cell identity and gain of properties of neural precursor/progenitor cells. Cell Biosci. 2017;7:61.
doi: 10.1186/s13578-017-0188-9
Zhang Z, Lei A, Xu L, Chen L, Chen Y, Zhang X, et al. Similarity in gene-regulatory networks suggests that cancer cells share characteristics of embryonic neural cells. J Biol Chem. 2017;292:12842–59.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.
Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer. 2011;12:23–38.
doi: 10.1038/nrc3169
Oliver TG, Read TA, Kessler JD, Mehmeti A, Wells JF, Huynh TT, et al. Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development. 2005;132:2425–39.
Paris L, Giardullo P, Leonardi S, Tanno B, Meschini R, Cordelli E, et al. Transgenerational inheritance of enhanced susceptibility to radiation-induced medulloblastoma in newborn Ptch1(+)/(−) mice after paternal irradiation. Oncotarget. 2015;6:36098–112.
Ishida Y, Takabatake T, Kakinuma S, Doi K, Yamauchi K, Kaminishi M, et al. Genomic and gene expression signatures of radiation in medulloblastomas after low-dose irradiation in Ptch1 heterozygous mice. Carcinogenesis. 2010;31:1694–701.
Mancuso M, Pazzaglia S, Tanori M, Hahn H, Merola P, Rebessi S, et al. Basal cell carcinoma and its development: insights from radiation-induced tumors in Ptch1-deficient mice. Cancer Res. 2004;64:934–41.
Fougerousse F, Bullen P, Herasse M, Lindsay S, Richard I, Wilson D, et al. Human-mouse differences in the embryonic expression patterns of developmental control genes and disease genes. Hum Mol Genet. 2000;9:165–73.
Inoue M, Kajiwara K, Yamaguchi A, Kiyono T, Samura O, Akutsu H, et al. Autonomous trisomic rescue of Down syndrome cells. Lab Invest. 2019;99:885–97.
Nakajima T, Ikeya M. Insights into the biology of fibrodysplasia ossificans progressiva using patient-derived induced pluripotent stem cells. Regen Ther. 2019;11:25–30.
doi: 10.1016/j.reth.2019.04.004
Watanabe N, Santostefano KE, Yachnis AT, Terada N. A pathologist’s perspective on induced pluripotent stem cells. Lab Invest. 2017;97:1126–32.
Hosoya M, Saeki T, Saegusa C, Matsunaga T, Okano H, Fujioka M, et al. Estimating the concentration of therapeutic range using disease-specific iPS cells: Low-dose rapamycin therapy for Pendred syndrome. Regen Ther. 2019;10:54–63.
Yagi M, Yamanaka S, Yamada Y. Epigenetic foundations of pluripotent stem cells that recapitulate in vivo pluripotency. Lab Invest. 2017;97:1133–41.
doi: 10.1038/labinvest.2017.87
Kojima J, Fukuda A, Taira H, Kawasaki T, Ito H, Kuji N, et al. Efficient production of trophoblast lineage cells from human induced pluripotent stem cells. Lab Invest. 2017;97:1188–200.
Masuda S, Matsuura K, Shimizu T. Preparation of iPS cell-derived CD31(+) endothelial cells using three-dimensional suspension culture. Regen Ther. 2018;9:1–9.
doi: 10.1016/j.reth.2018.06.004
Teshigawara R, Cho J, Kameda M, Tada T. Mechanism of human somatic reprogramming to iPS cell. Lab Invest. 2017;97:1152–7.
Wahid M, Jawed A, Mandal RK, Dar SA, Khan S, Akhter N, et al. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas. Crit Rev Oncol Hematol. 2016;98:235–41.
Tang JY, Ally MS, Chanana AM, Mackay-Wiggan JM, Aszterbaum M, Lindgren JA, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17:1720–31.
Ikemoto Y, Takayama Y, Fujii K, Masuda M, Kato C, Hatsuse H, et al. Somatic mosaicism containing double mutations in PTCH1 revealed by generation of induced pluripotent stem cells from nevoid basal cell carcinoma syndrome. J Med Genet. 2017;54:579–84.
Nishino K, Arai Y, Takasawa K, Toyoda M, Yamazaki-Inoue M, Sugawara T, et al. Epigenetic-scale comparison of human iPSCs generated by retrovirus, Sendai virus or episomal vectors. Regen Ther. 2018;9:71–8.
Nishino K, Toyoda M, Yamazaki-Inoue M, Fukawatase Y, Chikazawa E, Sakaguchi H, et al. DNA methylation dynamics in human induced pluripotent stem cells over time. PLoS Genet. 2011;7:e1002085.
doi: 10.1371/journal.pgen.1002085
Watanabe K, Kamiya D, Nishiyama A, Katayama T, Nozaki S, Kawasaki H, et al. Directed differentiation of telencephalic precursors from embryonic stem cells. Nat Neurosci. 2005;8:288–96.
Rho JY, Yu K, Han JS, Chae JI, Koo DB, Yoon HS, et al. Transcriptional profiling of the developmentally important signalling pathways in human embryonic stem cells. Hum Reprod. 2006;21:405–12.
Li Q, Lex RK, Chung H, Giovanetti SM, Ji Z, Ji H, et al. The pluripotency factor NANOG binds to GLI proteins and represses Hedgehog-mediated transcription. J Biol Chem. 2016;291:7171–82.
Lauth M, Bergstrom A, Shimokawa T, Toftgård R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A. 2007;104:8455–60.
Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt SN, Borges I, Ruiz i Altaba A. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J. 2010;29:2659–74.
Po A, Ferretti E, Miele E, De Smaele E, Paganelli A, Canettieri G, et al. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J. 2010;29:2646–58.
Wijgerde M, McMahon JA, Rule M, McMahon AP. A direct requirement for Hedgehog signaling for normal specification of all ventral progenitor domains in the presumptive mammalian spinal cord. Genes Dev. 2002;16:2849–64.
Cai C, Thorne J, Grabel L. Hedgehog serves as a mitogen and survival factor during embryonic stem cell neurogenesis. Stem Cells. 2008;26:1097–108.
doi: 10.1634/stemcells.2007-0684
Meng E, Hanna A, Samant RS, Shevde LA. The impact of Hedgehog signaling pathway on DNA repair mechanisms in human cancer. Cancers (Basel). 2015;7:1333–48.
Tripathi K, Mani C, Barnett R, Nalluri S, Bachaboina L, Rocconi RP, et al. Gli1 protein regulates the S-phase checkpoint in tumor cells via Bid protein, and its inhibition sensitizes to DNA topoisomerase 1 inhibitors. J Biol Chem. 2014;289:31513–25.
Dahmane N, Lee J, Robins P, Heller P, Ruiz i Altaba A. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature. 1997;389:876–81.
Nilsson M, Unden AB, Krause D, Malmqwist U, Raza K, Zaphiropoulos PG, et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci USA. 2000;97:3438–43.
Zhu H, Lo HW. The human glioma-associated oncogene homolog 1 (GLI1) family of transcription factors in gene regulation and diseases. Curr Genomics. 2010;11:238–45.
doi: 10.2174/138920210791233108